Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979295383> ?p ?o ?g. }
- W2979295383 endingPage "164" @default.
- W2979295383 startingPage "164" @default.
- W2979295383 abstract "Abstract Abstract 164FN2 Somatic gene therapy for X-linked severe combined immunodeficiency (X-SCID) using a MLV-based gammaretroviral vector expressing the IL-2 receptor gamma chain (MFG-γc) resulted in excellent immunologic reconstitution but also in insertional oncogenesis. In 5/20 treated children, T cell leukemia developed, with insertional activation of LMO2 proto-oncogene in 4 of the 5. We reasoned that replacing the virus-derived promoter and enhancer elements with a weaker cellular promoter would result in improved safety yet retain efficacy. We therefore generated the pSRS11.EFS.IL2RG.pre* self-inactivating (SIN) gammaretroviral vector in which expression of γc is controlled by an intronless EF1-α promoter, in a MLV vector devoid of the LTR U3 (enhancer/promoter) region. In preclinical studies we determined ‘relative safety' using several surrogate assays. In a reporter assay, the pSRS11.EFS.IL2RG.pre* vector when inserted into the oncogenic LMO2 locus induced LMO2 expression 6–90-fold less than the parent MFG vector (MFG-γc). pSRS11.EFS.IL2RG.pre* had lower activity in a murine in vitro immortalization assay (0.2 clones per 10e5 cells, fitness score 0.00007), compared to MFG-γc (0.54 clones per 10e5 cells, fitness score 0.00025). Peripheral blood and bone marrow from C57BL6 mice transplanted with murine bone marrow transduced with pSRS11.EFS.IL2RG.pre* and followed in primary recipients over 4 months and in secondary recipients over 1 year in vivo showed no evidence of vector associated leukemias. Deep sequencing demonstrated 8 of 3621 insertions into the MDS-associated gene Evi1 in mice transplanted with MFG-γc-transduced cells while there were none (0 of 2690 insertions into Evi1) in mice transplanted with pSRS11.EFS.IL2RG.pre* vector transduced cells (P=0.025). In preclinical efficacy studies, circulating T and B lymphocytes were detectable in the peripheral blood of 7/7 γc-deficient mice transplanted with pSRS11.EFS.IL2RG.pre* transduced cells while 4/4 mice repopulated with SFFV-eGFP transduced cells remained alymphoid. Experimental animals were sacrificed approximately five months post-transplant for analysis of immune reconstitution. Flow cytometric analysis of the spleens and bone marrow revealed restoration of mature B220+IgM+ B cells and NK cell populations in all mice transplanted with pSRS11.EFS.IL2RG.pre* transduced cells. CD4+ and CD8+ T cells were also detected in both tissues and in thymi recovered from transplanted animals. T cells in these mice proliferated in response to mitogenic stimuli. Immunoglobulin subclasses IgG1 and IgG2a detected in the plasma from pSRS11.EFS.IL2RG.pre* reconstituted mice also indicated restored B cell function in these animals. Human preclinical studies also supported the correction of XSCID cellular defects using this vector. Based on these data, a multi-institutional phase I/II trial was initiated with the pSRS11.EFS.IL2RG.pre* vector using an identical clinical protocol as in the previous X-SCID trials, to determine efficacy and safety compared with the MFG-γc vector. The first patient was treated in December 2010. Six months post-gene therapy, he has attained CD3 T cell count of >800, normal proliferation to mitogens, and normal NK cell numbers. He has cleared medically-resistant oral ulcers, and a rotavirus infection acquired post-gene therapy. Nearly all of the circulating T cells (86%) and 41% of his NK cells express γc, albeit at modestly lower density than normal, as expected. However, the early kinetics of T cell reconstitution was comparable to several subjects treated with MFG-γc. These data suggest that the improved safety profile demonstrated with numerous surrogate preclinical studies is associated with efficacious transgene expression and functional immune recovery in the initial human patient treated. Disclosures: Off Label Use: CliniMACS for selection of CD34+ hematopoietic cells. Baum:Patent office: Patents & Royalties." @default.
- W2979295383 created "2019-10-18" @default.
- W2979295383 creator A5001888046 @default.
- W2979295383 creator A5010459855 @default.
- W2979295383 creator A5012852870 @default.
- W2979295383 creator A5015856478 @default.
- W2979295383 creator A5016149531 @default.
- W2979295383 creator A5016535188 @default.
- W2979295383 creator A5017351450 @default.
- W2979295383 creator A5019430815 @default.
- W2979295383 creator A5027674192 @default.
- W2979295383 creator A5029004287 @default.
- W2979295383 creator A5029163913 @default.
- W2979295383 creator A5031275478 @default.
- W2979295383 creator A5031526764 @default.
- W2979295383 creator A5032230772 @default.
- W2979295383 creator A5034728481 @default.
- W2979295383 creator A5041017961 @default.
- W2979295383 creator A5047937141 @default.
- W2979295383 creator A5050971129 @default.
- W2979295383 creator A5053028197 @default.
- W2979295383 creator A5054362291 @default.
- W2979295383 creator A5055004103 @default.
- W2979295383 creator A5056346259 @default.
- W2979295383 creator A5056969520 @default.
- W2979295383 creator A5057948599 @default.
- W2979295383 creator A5059367719 @default.
- W2979295383 creator A5067822812 @default.
- W2979295383 creator A5068698149 @default.
- W2979295383 creator A5069311415 @default.
- W2979295383 creator A5073418464 @default.
- W2979295383 creator A5088946190 @default.
- W2979295383 date "2011-11-18" @default.
- W2979295383 modified "2023-09-27" @default.
- W2979295383 title "Somatic Gene Therapy for X-Linked Severe Combined Immunodeficiency Using a Self-Inactivating Modified Gammaretroviral Vector Results in An Improved Preclinical Safety Profile and Early Clinical Efficacy in a Human Patient" @default.
- W2979295383 doi "https://doi.org/10.1182/blood.v118.21.164.164" @default.
- W2979295383 hasPublicationYear "2011" @default.
- W2979295383 type Work @default.
- W2979295383 sameAs 2979295383 @default.
- W2979295383 citedByCount "3" @default.
- W2979295383 countsByYear W29792953832012 @default.
- W2979295383 countsByYear W29792953832013 @default.
- W2979295383 countsByYear W29792953832014 @default.
- W2979295383 crossrefType "journal-article" @default.
- W2979295383 hasAuthorship W2979295383A5001888046 @default.
- W2979295383 hasAuthorship W2979295383A5010459855 @default.
- W2979295383 hasAuthorship W2979295383A5012852870 @default.
- W2979295383 hasAuthorship W2979295383A5015856478 @default.
- W2979295383 hasAuthorship W2979295383A5016149531 @default.
- W2979295383 hasAuthorship W2979295383A5016535188 @default.
- W2979295383 hasAuthorship W2979295383A5017351450 @default.
- W2979295383 hasAuthorship W2979295383A5019430815 @default.
- W2979295383 hasAuthorship W2979295383A5027674192 @default.
- W2979295383 hasAuthorship W2979295383A5029004287 @default.
- W2979295383 hasAuthorship W2979295383A5029163913 @default.
- W2979295383 hasAuthorship W2979295383A5031275478 @default.
- W2979295383 hasAuthorship W2979295383A5031526764 @default.
- W2979295383 hasAuthorship W2979295383A5032230772 @default.
- W2979295383 hasAuthorship W2979295383A5034728481 @default.
- W2979295383 hasAuthorship W2979295383A5041017961 @default.
- W2979295383 hasAuthorship W2979295383A5047937141 @default.
- W2979295383 hasAuthorship W2979295383A5050971129 @default.
- W2979295383 hasAuthorship W2979295383A5053028197 @default.
- W2979295383 hasAuthorship W2979295383A5054362291 @default.
- W2979295383 hasAuthorship W2979295383A5055004103 @default.
- W2979295383 hasAuthorship W2979295383A5056346259 @default.
- W2979295383 hasAuthorship W2979295383A5056969520 @default.
- W2979295383 hasAuthorship W2979295383A5057948599 @default.
- W2979295383 hasAuthorship W2979295383A5059367719 @default.
- W2979295383 hasAuthorship W2979295383A5067822812 @default.
- W2979295383 hasAuthorship W2979295383A5068698149 @default.
- W2979295383 hasAuthorship W2979295383A5069311415 @default.
- W2979295383 hasAuthorship W2979295383A5073418464 @default.
- W2979295383 hasAuthorship W2979295383A5088946190 @default.
- W2979295383 hasConcept C104317684 @default.
- W2979295383 hasConcept C111599444 @default.
- W2979295383 hasConcept C111936080 @default.
- W2979295383 hasConcept C134305767 @default.
- W2979295383 hasConcept C150194340 @default.
- W2979295383 hasConcept C153911025 @default.
- W2979295383 hasConcept C203014093 @default.
- W2979295383 hasConcept C2778431562 @default.
- W2979295383 hasConcept C2779468541 @default.
- W2979295383 hasConcept C2780007613 @default.
- W2979295383 hasConcept C32470452 @default.
- W2979295383 hasConcept C40767141 @default.
- W2979295383 hasConcept C502942594 @default.
- W2979295383 hasConcept C54009773 @default.
- W2979295383 hasConcept C54355233 @default.
- W2979295383 hasConcept C86803240 @default.
- W2979295383 hasConcept C92087593 @default.
- W2979295383 hasConceptScore W2979295383C104317684 @default.
- W2979295383 hasConceptScore W2979295383C111599444 @default.
- W2979295383 hasConceptScore W2979295383C111936080 @default.
- W2979295383 hasConceptScore W2979295383C134305767 @default.
- W2979295383 hasConceptScore W2979295383C150194340 @default.
- W2979295383 hasConceptScore W2979295383C153911025 @default.
- W2979295383 hasConceptScore W2979295383C203014093 @default.